<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04585321</url>
  </required_header>
  <id_info>
    <org_study_id>EQI7_17_01</org_study_id>
    <nct_id>NCT04585321</nct_id>
  </id_info>
  <brief_title>Comparative Bioavailability and Local Tolerability of Two Topical Diclofenac Plasters Applied Once and Twice a Day</brief_title>
  <official_title>Comparative Bioavailability and Local Tolerability of Two Topical Diclofenac Plasters Applied Once and Twice a Day to Healthy Volunteers With a Repeat Dose Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fidia Farmaceutici s.p.a.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fidia Farmaceutici s.p.a.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Objectives Primary To evaluate the average bioequivalence in healthy volunteers between&#xD;
      medicinal product of Diclofenac Sodium 140mg Medicated Plaster EQI7 in comparison to the&#xD;
      reference medicinal product Flector®, applied once and twice a day.&#xD;
&#xD;
      Secondary To evaluate pharmacokinetic profile on Day 1, adhesivity, local tolerability and&#xD;
      safety of medicinal product Diclofenac Sodium 140mg Medicated Plaster EQI7 in healthy&#xD;
      volunteers in comparison to the reference medicinal product Flector®, applied once and twice&#xD;
      a day.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Objectives Primary To evaluate the average bioequivalence in healthy volunteers between&#xD;
      medicinal product of Diclofenac Sodium 140mg Medicated Plaster EQI7 in comparison to the&#xD;
      reference medicinal product Flector®, both formulated as topical plasters applied once and&#xD;
      twice a day.&#xD;
&#xD;
      Secondary To evaluate pharmacokinetic profile on Day 1, adhesivity, local tolerability and&#xD;
      safety of medicinal product Diclofenac Sodium 140mg Medicated Plaster EQI7 in healthy&#xD;
      volunteers in comparison to the reference medicinal product Flector®, both formulated as&#xD;
      topical plasters applied once and twice a day.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 28, 2017</start_date>
  <completion_date type="Actual">May 17, 2018</completion_date>
  <primary_completion_date type="Actual">May 17, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Css max (ng/mL) of Diclofenac Sodium 140mg Medicated Plaster EQI7 and Flector® topical plasters applied once and twice a day on Day 7 through Day 9</measure>
    <time_frame>Day 7 through Day 9</time_frame>
    <description>Css max on Day 7 through Day 9</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCττ (ng/mL*h) of Diclofenac Sodium 140mg Medicated Plaster EQI7 and Flector® topical plasters applied once and twice a day on Day 7 through Day 9</measure>
    <time_frame>Day 7 through Day 9</time_frame>
    <description>AUCττ on Day 7 through Day 9</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax (ng/mL) of Diclofenac Sodium 140mg Medicated Plaster EQI7 and Flector® topical plasters applied once and twice a day on Day 1</measure>
    <time_frame>Day 1</time_frame>
    <description>Cmax on Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (ng/mL*h) of Diclofenac Sodium 140mg Medicated Plaster EQI7 and Flector® topical plasters applied once and twice a day on Day 1</measure>
    <time_frame>Day 1</time_frame>
    <description>AUC on Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adhesivity of Diclofenac Sodium 140mg Medicated Plaster EQI7 in comparison to Flector® topical plasters applied once and twice a day with a 5-point ordinal scale, where 0= &gt;90%adhered and 4=plaster detached, from Day 1 for the entire study period</measure>
    <time_frame>From Day 1 for the entire study duration</time_frame>
    <description>Adhesivity of plasters with adhesivity 5-point ordinal scale:&#xD;
0 = &gt;90% adhered; 1 = &gt;75% to &lt;90% adhered; 2 = &gt;50% to &lt;75% adhered; 3 =&lt; 50% adhered but not detached; 4 = Plaster detached, from Day 1 for the entire study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local tolerability of Diclofenac Sodium 140mg Medicated Plaster EQI7 in comparison to Flector® topical plasters applied once and twice a day, with the irritation8-point scale, where 0=no evidence of irritation and 7=strong reaction, from Day1 onward</measure>
    <time_frame>From Day 1 for the entire study duration</time_frame>
    <description>Local tolerability: irritation 8-point categorical scale:0=no evidence of irritation;1=minimal erythema, barely perceptible;2=definite erythema, readily visible;3=minimal edema or minimal papular response;3=erythema and papules;4=definite edema;5=erythema, edema, and papules;6=vescicular eruption;7=strong reaction spreading beyond test site, from Day1 for the entire study duration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local tolerability of Diclofenac Sodium 140mg Medicated Plaster EQI7 in comparison to Flector® topical plasters applied once and twice a day, with the syntoms 4-point categorical scale score, where 0=absent and 3=severe, from Day1 onward</measure>
    <time_frame>From Day 1 for the entire study duration</time_frame>
    <description>Local tolerability: symptoms 4-point categorical scale:0=absent;1=mild;2=moderate;3=severe), from Day1 for the entire study duration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of heart rate in bpm during treatment with Diclofenac Sodium 140mg Medicated Plaster EQI7 and Flector® topical plasters applied once and twice a day on Day 1 of period 1 and Day 9 of period 2</measure>
    <time_frame>Day 1 of period 1 and Day 9 of period 2</time_frame>
    <description>Heart rate measurement in bpm on Day 1 of period 1 and Day 9 of period 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of systolic/diastolic blood pressure in mmHg during treatment with Diclofenac Sodium 140mg Medicated Plaster EQI7 and Flector® topical plasters applied once and twice a day on Day 1 of period 1 and Day 9 of period 2</measure>
    <time_frame>Day 1 of period 1 and Day 9 of period 2</time_frame>
    <description>Systolic/diastolic blood pressure in mmHg measurement on Day 1 of period 1 and Day 9 of period 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of body temperature in C degree during treatment with Diclofenac Sodium 140mg Medicated Plaster EQI7 and Flector® topical plasters applied once and twice a day on Day 1 of period 1 and Day 9 of period 2</measure>
    <time_frame>Day 1 of period 1 and Day 9 of period 2</time_frame>
    <description>Body temperature in C degrees measurement on Day 1 of period 1 and Day 9 of period 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematological analysis during treatment with Diclofenac Sodium 140mg Medicated Plaster EQI7 and Flector® topical plasters applied once and twice a day on Day 1 of period 1 and Day 9 of period 2</measure>
    <time_frame>Day 1 of period 1 and Day 9 of period 2</time_frame>
    <description>Haematological analysis on Day 1 of period 1 and Day 9 of period 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical analysis during treatment with Diclofenac Sodium 140mg Medicated Plaster EQI7 and Flector® topical plasters applied once and twice a day on Day 1 of period 1 and Day 9 of period 2</measure>
    <time_frame>Day 1 of period 1 and Day 9 of period 2</time_frame>
    <description>Biochemical analysis on Day 1 of period 1 and Day 9 of period 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virological tests during treatment with Diclofenac Sodium 140mg Medicated Plaster EQI7 and Flector® topical plasters applied once and twice a day on Day 1 of period 1 and Day 9 of period 2</measure>
    <time_frame>Day 1 of period 1 and Day 9 of period 2</time_frame>
    <description>Virological tests on Day 1 of period 1 and Day 9 of period 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinalysis during treatment with Diclofenac Sodium 140mg Medicated Plaster EQI7 and Flector® topical plasters applied once and twice a day on Day 1 of period 1 and Day 9 of period 2</measure>
    <time_frame>Day 1 of period 1 and Day 9 of period 2</time_frame>
    <description>Urinalysis on Day 1 of period 1 and Day 9 of period 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-lead ECG evaluation during treatment with Diclofenac Sodium 140mg Medicated Plaster EQI7 and Flector® topical plasters applied once and twice a day on Day 1 of period 1 and Day 9 of period 2</measure>
    <time_frame>Day 1 of period 1 and Day 9 of period 2</time_frame>
    <description>12-lead ECG on Day 1 of period 1 and Day 9 of period 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events using Diclofenac Sodium 140mg Medicated Plaster EQI7 and Flector® topical plasters applied once and twice a day from Day 1 for the entire study duration</measure>
    <time_frame>From Day 1 for the entire study duration</time_frame>
    <description>Incidence of adverse events from Day 1 for the entire study duration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Bioequivalence Study</condition>
  <arm_group>
    <arm_group_label>T-R</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Part 1 (QD) and part 2 (BID):&#xD;
Period 1: Test drug (T): Diclofenac Sodium 140mg Medicated Plaster EQI7, topical plaster.&#xD;
Period 2: Reference drug (R): Flector® topical plaster containing 180 mg of diclofenac hydroxyethylpyrrolidine equivalent to 140 mg of sodium diclofenac.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R-T</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Part 1 (QD) and part 2 (BID):&#xD;
Period 1: Reference drug (R): Flector® topical plaster containing 180 mg of diclofenac hydroxyethylpyrrolidine equivalent to 140 mg of sodium diclofenac.&#xD;
Period 2: Test drug (T): Diclofenac Sodium 140mg Medicated Plaster EQI7, topical plaster.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac Sodium 140mg Medicated Plaster</intervention_name>
    <description>Part 1: two seven-day study periods, separated by at least 7 days of wash-out. In the first period, a single plaster of Test Drug or Reference Drug will be applied on the back (lumbar region) for seven consecutive days. In the second period, a single plaster of the Reference Drug or Test Drug will be applied on the back (lumbar region) daily for seven consecutive days.&#xD;
Part 2: two seven-day study periods separated by at least 7 days of wash-out. In the first period, the Test Drug or Reference Drug plaster will be applied on the back (lumbar region) twice a day. In the second period, the Reference Drug or Test Drug plaster will be applied on the back (lumbar region) twice a day.</description>
    <arm_group_label>R-T</arm_group_label>
    <arm_group_label>T-R</arm_group_label>
    <other_name>EQI7</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flector® topical plaster containing 180 mg of diclofenac hydroxyethylpyrrolidine equivalent to 140 mg of sodium diclofenac</intervention_name>
    <description>Part 1: two seven-day study periods, separated by at least 7 days of wash-out. In the first period, a single plaster of Test Drug or Reference Drug will be applied on the back (lumbar region) for seven consecutive days. In the second period, a single plaster of the Reference Drug or Test Drug will be applied on the back (lumbar region) daily for seven consecutive days.&#xD;
Part 2: two seven-day study periods separated by at least 7 days of wash-out. In the first period, the Test Drug or Reference Drug plaster will be applied on the back (lumbar region) twice a day. In the second period, the Reference Drug or Test Drug plaster will be applied on the back (lumbar region) twice a day.</description>
    <arm_group_label>R-T</arm_group_label>
    <arm_group_label>T-R</arm_group_label>
    <other_name>Flector</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females, Caucasian/White aged between 18 and 55 years.&#xD;
&#xD;
          2. BMI between 19 and 29 kg/m² included&#xD;
&#xD;
          3. Normal or non-clinical significant findings on the physical examination&#xD;
&#xD;
          4. Normal or non-clinical significant finding on the laboratory evaluations. Laboratory&#xD;
             values outside the normal range will be carefully evaluated by the clinical&#xD;
             investigator. Subject showing safety laboratory values outside the normal range, but&#xD;
             judged not clinically significant, may be allowed to enter the study. For sodium and&#xD;
             potassium no values outside the normal range will be allowed.&#xD;
&#xD;
          5. Willing and able to understand and sign an approved Informed Consent form.&#xD;
&#xD;
          6. If female, they must not be pregnant or breast feeding and using an effective&#xD;
             contraception method during the study (hormonal, such as birth control pill, or&#xD;
             barrier method, such as condom or diaphragm, or intrauterine, such as spiral).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of alcohol or drug abuse.&#xD;
&#xD;
          2. Smokers of more than 10 cigarettes/day.&#xD;
&#xD;
          3. History of gastrointestinal, renal, hepatic, pulmonary or cardiovascular disease; or&#xD;
             history of epilepsy, asthma, diabetes, psychosis or glaucoma.&#xD;
&#xD;
          4. History of allergic response to diclofenac or related drugs, namely non-steroidal&#xD;
             anti-inflammatory agents&#xD;
&#xD;
          5. Presence or history of allergies requiring acute or chronic treatment (except seasonal&#xD;
             allergic rhinitis)&#xD;
&#xD;
          6. Participation in a previous clinical trial within the past 6 months.&#xD;
&#xD;
          7. Blood donation of 250 ml or more within the past 3 months.&#xD;
&#xD;
          8. Treatment with any known enzyme inhibiting or inducing agents (barbiturates,&#xD;
             phenothiazines, etc.) within the past 4 weeks.&#xD;
&#xD;
          9. Positive to HIV test and/or Hepatitis B and C tests.&#xD;
&#xD;
         10. Positive to drugs of abuse qualitative screen in urine.&#xD;
&#xD;
         11. Use of any prescription or over-the-counter medication on a regular basis.&#xD;
&#xD;
         12. Drinking excessive amounts of tea, cacao, coffee and/or beverages containing caffeine&#xD;
             (&gt; 5 cups/day) or wine (&gt; 0,5 l/day) or spirits (&gt; 50 ml/day)&#xD;
&#xD;
         13. In the judgement of the Clinical Investigator subjects likely to be not compliant or&#xD;
             cooperative during the study.&#xD;
&#xD;
         14. Irritation scale score higher than zero at the sites of application.&#xD;
&#xD;
         15. Presence of skin injuries at the sites of application.&#xD;
&#xD;
         16. An acquired tan (by sun or lamp) in the previous 2 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicola Giordan</last_name>
    <role>Study Director</role>
    <affiliation>Fidia Farmaceutici s.p.a.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRC Centro Ricerche Cliniche di Verona s.r.l. c/o Azienda Ospedaliera Universitaria Integrata Verona</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 2, 2020</study_first_submitted>
  <study_first_submitted_qc>October 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>October 7, 2020</last_update_submitted>
  <last_update_submitted_qc>October 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Diclofenac hydroxyethylpyrrolidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

